Keywords
Continuous glucose monitoring
FreeStyle Libre 2
Clinical Recommendation
Pediatrics
How to Cite
Abstract
Context: Continuous glucose monitoring (CGM) has significantly improved the management of type 1 diabetes in children and adolescents. In Colombia, two systems are marketed within the FreeStyle Libre family: FreeStyle Libre (first-generation isCGM without alarms, approved for ? 4 years) and FreeStyle Libre 2 Plus (FSL2 Plus), which can operate as rtCGM with the FreeStyle LibreLink application (with alarms) or as isCGM with a reader (without alarms), approved for ? 2 years.
Objective: To develop clinical recommendations for the use of FreeStyle Libre 2 Plus in children and adolescents with type 1 diabetes in Colombia, integrating scientific evidence with contextualized clinical experience.
Methodology: A structured literature review (2015–2024) was conducted on the use of FreeStyle Libre (FSL2 and FSL2 Plus) in pediatric type 1 diabetes. A nominal group technique involving six pediatric endocrinologists was used to formulate recommendations adapted to the Colombian context, with the support of an independent methodological team.
Results: A total of 22 recommendations were agreed upon and organized into five thematic areas: initiation of CGM, structured education, use of metrics and therapeutic targets, psychosocial support, and coordinated care. The recommendations cover practical aspects such as patient selection, alarm configuration when using the application, and scan frequency when using the reader, metric interpretation, and educational and emotional support.
Conclusions: This document provides practical guidance for healthcare professionals in Colombia and may be adaptable to other countries with similar healthcare systems. The implementation of the FreeStyle Libre 2 Plus system could promote safer, more equitable, and family-centered clinical decision-making.
References
Edge J, Acerini C, Campbell F, Hamilton-Shield J, Moudiotis C, Rahman S, et al. An alternative sensor-based method for glucose monitoring in children and young people with diabetes. Arch Dis Child. 2017;102(6):543–549. https://doi.org/10.1136/archdischild-2016-311530
Tauschmann M, Hermann JM, Freiberg C, Papsch M, Thon A, Heidtmann B, et al. Reduction in diabetic ketoacidosis and severe hypoglycemia in pediatric type 1 diabetes during the first year of continuous glucose monitoring: A multicenter analysis of 3,553 subjects from the DPV registry. Diabetes Care. 2020;43(3):e40–42. https://doi.org/10.2337/dc19-1358
Landau Z, Abiri S, Gruber N, Levy-Shraga Y, Brener A, Lebenthal Y, et al. Use of flash glucose-sensing technology (FreeStyle Libre) in youth with type 1 diabetes: AWeSoMe study group real-life observational experience. Acta Diabetol. 2018;55(12):1303–1310. https://doi.org/10.1007/s00592-018-1218-8
Klonoff DC, Gabbay M, Moon SJ, Wilmot EG. Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring. J Diabetes Sci Technol. 2025;19(5):1392–1399. https://doi.org/10.1177/19322968241250357
Krakauer M, Travassos S, Rodacki M, Gabbay MAL, Vianna AGD, Scharf M, et al. Glucose alarms approach with flash glucose monitoring system: A narrative review of clinical benefits. Diabetol Metab Syndr. 2025;17(1):276. https://doi.org/10.1186/s13098-025-01797-3
Alva S, Bailey T, Brazg R, Budiman ES, Castorino K, Christiansen MP, et al. Accuracy of a 14-day factory-calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes. J Diabetes Sci Technol. 2022;16(1):70–77. https://doi.org/10.1177/1932296820958754
Así Vamos en Salud. Cobertura de afiliación 7/11/2024 [Internet]. Bogotá: Así Vamos en Salud; 2024 [citado 30 abr 2025]. Disponible en: https://www.asivamosensalud.org/publicaciones/noticias-especializadas/cobertura-de-afiliacion-7112024
Organización para la Cooperación y el Desarrollo Económicos (OCDE). Health at a Glance 2023 [Internet]. París: OCDE; 2023 [citado 30 abr 2025]. Disponible en: https://www.oecd.org/content/dam/oecd/en/publications/reports/2023/11/health-at-a-glance-2023_e04f8239/7a7afb35-en.pdf
Mejia E, Lewis AGC, Garcés-Palacio IC, Hernandez DM, Chamberlain RM, Soliman AS. Relationship between universal health insurance benefits and prostate cancer mortality in Colombia. BMC Public Health. 2024;24:2667. https://doi.org/10.1186/s12889-024-20117-4
Espinosa O, Friebel R, Bejarano V, Arias ML, Husereau D, Smith A. Study on the concentration, distribution, and persistence of health spending for the contributory scheme in Colombia. BMC Health Serv Res. 2024;24:1225. https://doi.org/10.1186/s12913-024-11636-2
Allen J, Dyas J, Jones M. Building consensus in health care: A guide to using the nominal group technique. Br J Community Nurs. 2004;9(3):110–114. https://doi.org/10.12968/bjcn.2004.9.3.12432
Van de Ven AH, Delbecq AL. The nominal group as a research instrument for exploratory health studies. Am J Public Health. 1972;62(3):337–342. https://doi.org/10.2105/AJPH.62.3.337
Suárez-Ayala DV, Forero-Ronderos C, Coll M, Duran P, Cespedes C, Suárez-Ayala DV, et al. Continuous glucose monitoring. Which is the evidence in children? Andes Pediatr. 2021;92(4):617–625. https://doi.org/10.32641/andespediatr.v92i4.2973
American Diabetes Association. Standards of medical care in diabetes—2020 abridged for primary care providers. Clin Diabetes. 2020;38(1):10–38. https://doi.org/10.2337/cd20-as01
American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S126–144. https://doi.org/10.2337/dc24-S007
DiMeglio LA, Acerini CL, Codner E, Craig ME, Hofer SE, Pillay K, et al. ISPAD clinical practice consensus guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19(Suppl 27):105–114. https://doi.org/10.1111/pedi.12737
Libman I, Haynes A, Lyons S, Pradeep P, Rwagasor E, Tung JY, et al. ISPAD clinical practice consensus guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2022;23(8):1160-1174. https://doi.org/10.1111/pedi.13454
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603. https://doi.org/10.2337/dci19-0028
Tauschmann M, Forlenza G, Hood K, Cardona-Hernandez R, Giani E, Hendrieckx C, et al. ISPAD clinical practice consensus guidelines 2022: Diabetes technologies: Glucose monitoring. Pediatr Diabetes. 2022;23(8):1390–1405. https://doi.org/10.1111/pedi.13451
Wright LAC, Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: Time in range, hypoglycemia, and other parameters. Diabetes Technol Ther. 2017;19(Suppl 2):S16-S26. https://doi.org/10.1089/dia.2017.0029
Jefferies CA, Boucsein A, Styles SE, Chamberlain B, Michaels VR, Crockett HR, et al. Effects of 12-Week Freestyle Libre 2.0 in children with type 1 diabetes and elevated HbA1c: A multicenter randomized controlled trial. Diabetes Technol Ther. 2023;25(12):827–835. https://doi.org/10.1089/dia.2023.0292
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Revista Colombiana de Endocrinología, Diabetes & Metabolismo